Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LIXT Lixte Biotechnology Holdings Inc.

Market Closed 12-12 16:00:00 EST

4.05

-0.15

-3.57%

盘后4.08

+0.03+0.74%

19:52 EST

High4.17	Low4.01	Vol52.06K
Open4.12	D1 Closing4.20	Amplitude3.81%
Mkt Cap23.10M	Tradable Cap21.91M	Total Shares5.70M
T/O212.10K	T/O Rate0.96%	Tradable Shares5.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LIXT","market":"US","secType":"STK","nameCN":"Lixte Biotechnology Holdings Inc.","latestPrice":4.05,"timestamp":1765573200000,"preClose":4.2,"halted":0,"volume":52064,"hourTrading":{"tag":"盘后","latestPrice":4.08,"preClose":4.05,"latestTime":"19:52 EST","volume":182,"amount":740.391,"timestamp":1765587136504},"delay":0,"floatShares":5410500,"shares":5704200,"eps":-1.211027,"marketStatus":"Market Closed","change":-0.15,"latestTime":"12-12 16:00:00 EST","open":4.12,"high":4.17,"low":4.01,"amount":212100.874336,"amplitude":0.038095,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.211027,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1606280400000,"exchange":"NASDAQ","adjPreClose":4.2,"preHourTrading":{"tag":"盘前","latestPrice":4.1999,"preClose":4.2,"latestTime":"09:15 EST","volume":50,"amount":209.9975,"timestamp":1765548933244},"postHourTrading":{"tag":"盘后","latestPrice":4.08,"preClose":4.05,"latestTime":"19:52 EST","volume":182,"amount":740.391,"timestamp":1765587136504},"volumeRatio":0.5546618486972571},"requestUrl":"/m/hq/s/LIXT","defaultTab":"news","newsList":[{"id":"2590546572","title":"Lixte Biotechnology Holdings Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590546572","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590546572?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:52","pubTimestamp":1765482745,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. held its Annual Meeting on December 8, 2025. Shareholders approved the election of Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway, Lourdes Felix, and Guy Primus to the board of directors. The appointment of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. Shareholders also approved an amendment to the 2020 Plan, increasing the number of shares of common stock available for issuance from 2.75 million to 3.5 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLCR9SZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2589035560","title":"Lixte Biotechnology Holdings Inc. Outlines Strategy to Expand Oncology Platform with Complementary Modalities, Advancing PP2A Inhibitor Development and Integrating Radiotherapy Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589035560","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589035560?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:30","pubTimestamp":1765200652,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. Outlines Strategy to Expand Oncology Platform with Complementary Modalities, Advancing PP2A Inhibitor Development and Integrating Radiotherapy Technologies. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL8qsf6j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2588221046","title":"Lixte Biotechnology Holdings Inc. Outlines Strategy to Advance LB-100 Combination Therapy, Strengthen Financial Foundation, and Support Multi-Year Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2588221046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588221046?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766845,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. Outlines Strategy to Advance LB-100 Combination Therapy, Strengthen Financial Foundation, and Support Multi-Year Clinical Development. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL5rGJKg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2586551402","title":"Lixte Biotechnology Acquires Liora Technologies for Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2586551402","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586551402?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:26","pubTimestamp":1764109606,"startTime":"0","endTime":"0","summary":"An update from Lixte Biotechnology Holdings ( ($LIXT) ) is now available. On November 24, 2025, LIXTE Biotechnology Holdings completed the acquisit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-acquires-liora-technologies-for-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-acquires-liora-technologies-for-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2586724874","title":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724874","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586724874?lang=en_us&edition=fundamental","pubTime":"2025-11-25 23:45","pubTimestamp":1764085504,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Kohl'sEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL6N3X10WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBY","SPOT","TITN","LU0323591593.USD","IE00BN0W2T93.GBP","HL","CDE","LIXT","PTCT","SYM","LU1116320737.USD","KEYS","SG9999000418.SGD","LU0784383803.USD","CDW","ZM","LU1066051498.USD","FLY","FCX","ATAT","ADI","KSS","LU1815336760.USD","ALUR","APD","UPWK","FLNC","LU2290526834.HKD","BK4548","DD","SCCO","ZETA","AMAT","ABCB","ESPR","IRD","ANF","FIBK","SRPT","VST","BK4541"],"gpt_icon":1},{"id":"2586476925","title":"BUZZ-Lixte rises after buying UK firm to enter proton therapy cancer care","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476925","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586476925?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:53","pubTimestamp":1764078785,"startTime":"0","endTime":"0","summary":"BUZZ-Lixte rises after buying UK firm to enter proton therapy cancer care** Shares of drug developer Lixte Biotechnology LIXT.O rise 7% to $4.78 premarket** Co says it acquired Liora Technologies Europe, which develops proton therapy systems for cancer treatment** Liora's flagship \"LiGHT System\" aims to deliver high-precision proton therapy at lower cost and fewer sessions - LIXT** LIXT says system installed at UK's STFC Daresbury Lab; plans to create a center of excellence for cancer care** Deal expands co beyond cancer drugs into radiotherapy; complements trials of its cancer therapy LB-100 for ovarian and colon cancer** Proton therapy is a type of radiation treatment for cancer that uses protons instead of X-rays to target tumors** Up to last close, stock up ~120% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4N3X10WN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2586476409","title":"Lixte Biotechnology acquires Liora’s proton therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476409","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586476409?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:45","pubTimestamp":1764078350,"startTime":"0","endTime":"0","summary":"LIXTE Biotechnology (LIXT) announced it has completed the acquisition of Liora Technologies Europe, a UK-based company pioneering electronically co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lixte-biotechnology-acquires-lioras-proton-therapy-platform-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lixte-biotechnology-acquires-lioras-proton-therapy-platform-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2586647543","title":"Lixte Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2586647543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586647543?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:30","pubTimestamp":1764077401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUA6CMTN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","LIXTW","BK4139"],"gpt_icon":0},{"id":"2576412776","title":"Lixte Biotechnology Holdings Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2576412776","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576412776?lang=en_us&edition=fundamental","pubTime":"2025-10-17 05:26","pubTimestamp":1760650014,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. has announced that it will hold its 2025 Annual Meeting of Stockholders on December 8, 2025. During the meeting, shareholders will be asked to vote on the election of five nominees for director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL6bfF2h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2575745330","title":"Lixte Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate Lb-100, Strategic Oncology Business Development and Acquisition Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2575745330","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575745330?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:00","pubTimestamp":1760616004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA3W1QLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIXTW","LIXT"],"gpt_icon":0},{"id":"2567360128","title":"Lixte Biotechnology Holdings Inc. Announces Leadership Reshuffle with Geordan Pursglove as CEO and Bas van der Baan as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2567360128","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567360128?lang=en_us&edition=fundamental","pubTime":"2025-09-16 05:41","pubTimestamp":1757972467,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. Announces Leadership Reshuffle with Geordan Pursglove as CEO and Bas van der Baan as Chief Scientific Officer. Lixte Biotechnology Holdings Inc. has announced significant management changes as part of its strategic realignment. Geordan Pursglove has been appointed as Chairman and CEO, while former CEO Bas van der Baan has transitioned to the role of Chief Scientific Officer. These changes are aimed at sharpening the company's focus on scientific development and operational strategy. The company has also reconstituted its Scientific Advisory Committee and relocated its headquarters to Boca Raton, Florida, signaling a renewed commitment to its growth and innovation objectives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDLb0BTjT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2566291308","title":"Lixte Biotechnology Invests $2.6M in Cryptocurrencies","url":"https://stock-news.laohu8.com/highlight/detail?id=2566291308","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566291308?lang=en_us&edition=fundamental","pubTime":"2025-09-12 01:47","pubTimestamp":1757612873,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Lixte Biotechnology Holdings ( ($LIXT) ). On September 10, 2025, LIXTE Biotechnology Holdings announced a $2.6 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-invests-2-6m-in-cryptocurrencies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-invests-2-6m-in-cryptocurrencies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2566982087","title":"Lixte Biotechnology purchases 10.5 Bitcoin, 300 Ethereum  for $2.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2566982087","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566982087?lang=en_us&edition=fundamental","pubTime":"2025-09-11 04:35","pubTimestamp":1757536540,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology (LIXT) announced it has made an initial purchase of cryptocurrencies to further diversify its treasury holdings and for potenti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lixte-biotechnology-purchases-10-5-bitcoin-300-ethereum-for-2-6m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lixte-biotechnology-purchases-10-5-bitcoin-300-ethereum-for-2-6m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QETH","BK4588","MBTmain","US3Y.BOND","US6M.BOND","FETH","METHmain","BK4601","US2Y.BOND","US12M.BOND","US5Y.BOND","US30Y.BOND","LIXT","BK4594","EZET","CETH","BK4585","US7Y.BOND","ETHV","BK4139","US10Y.BOND"],"gpt_icon":0},{"id":"2566984763","title":"Lixte Biotechnology Holdings Inc - Purchases 10.5 Bitcoin and 300 Ethereum for $2.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2566984763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566984763?lang=en_us&edition=fundamental","pubTime":"2025-09-11 04:10","pubTimestamp":1757535046,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nFWN3UX1BI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","LIXTW","BK4139"],"gpt_icon":0},{"id":"2566498997","title":"Lixte Biotechnology Holdings Inc. Files Initial Beneficial Ownership Statement for Director Guy Primus","url":"https://stock-news.laohu8.com/highlight/detail?id=2566498997","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566498997?lang=en_us&edition=fundamental","pubTime":"2025-09-11 02:20","pubTimestamp":1757528434,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. has filed an initial statement of beneficial ownership. The filing names Guy Warren Primus as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL4vy6G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2565156849","title":"Lixte Biotechnology Holdings Inc. Announces Breakthrough Clinical Trial for LB-100, the World's Only Clinical-Stage PP2A Inhibitor, Targeting Cancer Treatment Synergies","url":"https://stock-news.laohu8.com/highlight/detail?id=2565156849","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565156849?lang=en_us&edition=fundamental","pubTime":"2025-09-05 20:35","pubTimestamp":1757075754,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. Announces Breakthrough Clinical Trial for LB-100, the World's Only Clinical-Stage PP2A Inhibitor, Targeting Cancer Treatment Synergies. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via Newsfile  on September 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL8jvSkZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2565304355","title":"Lixte Biotechnology Holdings Inc. Files Initial Statement of Beneficial Ownership for Director Felix Lourdes","url":"https://stock-news.laohu8.com/highlight/detail?id=2565304355","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565304355?lang=en_us&edition=fundamental","pubTime":"2025-09-05 01:53","pubTimestamp":1757008436,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. has filed an initial statement of beneficial ownership. The filing notes that Felix Lourdes holds the position of Director within the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL1z4qXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2564839464","title":"BRIEF-Lixte Biotechnology Holdings Inc - Peter Stazzone Has Been Named Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2564839464","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564839464?lang=en_us&edition=fundamental","pubTime":"2025-09-03 22:30","pubTimestamp":1756909817,"startTime":"0","endTime":"0","summary":"BRIEF-Lixte Biotechnology Holdings Inc - Peter Stazzone Has Been Named Chief Financial OfficerSept 3 (Reuters) - Lixte Biotechnology Holdings Inc LIXT.O:LIXTE BIOTECHNOLOGY HOLDINGS APPOINTS TWO NEW B","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nTUA7KHWQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXTW","LIXT"],"gpt_icon":0},{"id":"2564239878","title":"Lixte Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2564239878","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564239878?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:00","pubTimestamp":1756900803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nTUA7KHWQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXTW","BK4139","LIXT"],"gpt_icon":0},{"id":"2562746280","title":"24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2562746280","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562746280?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:15","pubTimestamp":1756296900,"startTime":"0","endTime":"0","summary":"New Peer-Reviewed Publication Highlights Landmark Meeting Co-Sponsored by LIXTEDENVER, Aug.  27, 2025  (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/27/3139990/0/en/24-7-Market-News-LIXTE-Showcases-LB-100-at-First-Global-Conference-on-Oncogenic-Signaling-Activation-as-Cancer-Therapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4233","LB","LIXT","BK4213"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lixte.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.1474},{"period":"3month","weight":-0.3256},{"period":"6month","weight":2.5526},{"period":"1year","weight":1.1204},{"period":"ytd","weight":0.9954}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.183375},{"month":2,"riseRate":0.714286,"avgChangeRate":0.106103},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.047366},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.105051},{"month":5,"riseRate":0.375,"avgChangeRate":-0.005082},{"month":6,"riseRate":0.5,"avgChangeRate":0.031165},{"month":7,"riseRate":0.625,"avgChangeRate":0.400968},{"month":8,"riseRate":0.5,"avgChangeRate":0.097631},{"month":9,"riseRate":0.375,"avgChangeRate":0.00973},{"month":10,"riseRate":0.375,"avgChangeRate":-0.019298},{"month":11,"riseRate":0.375,"avgChangeRate":-0.035386},{"month":12,"riseRate":0.25,"avgChangeRate":-0.14188}],"exchange":"NASDAQ","name":"Lixte Biotechnology Holdings Inc.","nameEN":"Lixte Biotechnology Holdings Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lixte Biotechnology Holdings Inc.,LIXT,Lixte Biotechnology Holdings Inc.股票,Lixte Biotechnology Holdings Inc.股票老虎,Lixte Biotechnology Holdings Inc.股票老虎国际,Lixte Biotechnology Holdings Inc.行情,Lixte Biotechnology Holdings Inc.股票行情,Lixte Biotechnology Holdings Inc.股价,Lixte Biotechnology Holdings Inc.股市,Lixte Biotechnology Holdings Inc.股票价格,Lixte Biotechnology Holdings Inc.股票交易,Lixte Biotechnology Holdings Inc.股票购买,Lixte Biotechnology Holdings Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction